Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acucela, a clinical-stage biotechnology company, has dosed the first subject in a Phase I trial for its lead compound ACU-02.
Subscribe to our email newsletter
The single-site trial is enrolling healthy normal volunteers in a double-masked, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of ACU-02.
ACU-02 is an orally available small molecule being developed for the treatment of the dry form of age-related macular degeneration (AMD).
Ryo Kubota, CEO of Acucela, said: “We believe that ACU-02 provides significant promise for the millions of patients suffering from AMD, and we hope to be able to someday provide these patients with a treatment that is delivered in the form of a pill rather than an injection into the eye.”